Diquafosol may benefit DED patients

Article

Diquafosol may have a role in the management of dry eye disease (DED), according to a recently published review.

Diquafosol may have a role in the management of dry eye disease (DED), according to a recent review published in Clinical Ophthalmology.

Diquafosol is a uridine nucleotide analogue that is also a P2Y2 receptor agonist. Several randomized controlled trials have shown that the application of topical diquafosol significantly improves the objective markers of DED, including corneal and conjunctival fluorescein staining, tear film break-up time, and Schirmer's test scores. These improvements, however, are accompanied by only partial improvements in patient symptoms.

Both animal and human studies have shown that native P2Y2 agonists may be released at the ocular surface in response to trauma, and also shown to have numerous effects including increased mucin secretion, decreased fluorescein penetrance, accelerated wound healing, and the opening of chloride channels in the apical membrane.

"Progress in the understanding of dry eye pathophysiology and advances in diagnostic methods will help us better understand the place of diquafosol in the overall picture of DED management, overcome the discrepancy between signs and symptoms and find new markers to gauge efficacy in future clinical trials," wrote lead author Oliver C.F. Lau, Sydney Eye Hospital, Sydney, NSW, Australia, and co-authors.

"Further studies may be useful to clarify its role in specific subgroups of DED, such as meibomian gland dysfunction, Sjögren's syndrome, or DED recalcitrant to more traditional therapies. Longer-duration studies, as well as studies examining the effect of diquafosol on corneal sensation and nerve structure, and potential synergistic interplay between diquafosol and other therapeutic agents such as ocular lubri¬cants, traditional topical immunomodulatory agents such as prednisolone and cyclosporine, and newer targeted molecular agents would also be of great interest," the authors concluded.

To view the abstract, click here.

Newsletter

Join ophthalmologists across Europe—sign up for exclusive updates and innovations in surgical techniques and clinical care.

Recent Videos
Christine Curcio, PhD, of the University of Alabama at Birmingham Heersink School of Medicine, shares histology update and revised nomenclature for OCT with Sheryl Stevenson of the Eye Care Network and Ophthalmology Times
SriniVas R. Sadda, MD, FARVO, shares key points from his retina presentation at the International SPECTRALIS Symposium
Robert Sergott, MD, describes fluorescence lifetime imaging ophthalmoscopy (FLIO) and the International SPECTRALIS Symposium – And Beyond (ISS) in Heidelberg, Germany.
Rayaz Malik, MBChB, PhD, a professor of medicine at Weill Cornell Medicine - Qatar, spoke with Ophthalmology Times Europe about his presentation. It's titled "An eye on neurodegenerative diseases: Challenging the dogma" at the International SPECTRALIS Sympsoium. In conversation with Hattie Hayes, Ophthalmology Times Europe
Anat Loewenstein, MD, describes her presentation on remote imaging for age-related macular degeneration and geographic atrophy at the International SPECTRALIS Symposium, in conversation with Hattie Hayes of Ophthalmology Times Europe
Tyson Brunstetter, OD, PhD, a US Navy Aerospace Optometrist at the NASA Johnson Space Center in Houston, Texas, shares key takeaways from his keynote at the International SPECTRALIS Symposium (ISS)
Rayaz Malik, MBChB, PhD, shares his presentation, titled An eye on neurodegenerative diseases: Challenging the dogma, at this year's International SPECTRALIS Symposium
At the Retina World Congress, Siegfried Priglinger, MD, speaks about ensuring the best outcomes for preschool-aged patients
At the 2025 ASCRS meeting, Robert Ang, MD said small aperture IOLs can benefit all patients, especially those with complex corneas or who have undergone previous corneal refractive surgery
Viha Vig, MBChB graduate student at the University of Auckland, New Zealand, discusses her poster presentation on the relationship between mitochondiral disease, Alzheimer disease, and other types of dementia.
© 2025 MJH Life Sciences

All rights reserved.